Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.

Much of cell behavior is governed by the actions of biomolecular condensates: building block molecules that glom together and ...

AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...

Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...

Pathmaker's MyoRegulator is designed to ease hyperexcitability and delivers an electrical current to the spinal cord and ...

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...

Find out about the new ALS blood test that offers accurate diagnosis and could replace traditional invasive testing methods.

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

ALS impacts tens of thousands of people across the United States, and hundreds in Arizona. There's research being done in the Valley that can hopefully help contribute to ending ALS.

Sarasota-Manatee partnership offers free hearing support; job fairs in Bradenton, Sarasota; Goodwill opens LWR outlet; arts ...